In the News

Connect with us

Stay Informed.
Get the latest news and updates on MSK’s cancer care and research breakthroughs sent straight to your inbox with our e-newsletters.
Newsletter Sign Up
484 News Items found
MSK Nassau
Feature
7 Reasons to Come to MSK Nassau for Cancer Care

Learn more about world-class cancer care on Long Island at MSK Nassau.
Lymphedema can produce uncomfortable swelling in the arms or legs in the months and years following cancer treatment.
In the Lab
Could a Topical Cream Prevent Lymphedema? Study in Mice Suggests Yes

By blocking a source of inflammation in the skin, it may be possible to prevent or treat lymphedema, a common and debilitating cancer complication.
Memorial Sloan Kettering surgeon Prasad Adusumilli
Q&A
CAR T Cell Therapy Shows Promise for Treating Mesothelioma

A combination immunotherapy approach using CAR T cells could be an effective new way to treat mesothelioma.
Dr. Craig Thompson in his lab at the Sloan Kettering Institute
New MSK Research Reveals How Mitochondria Function Under Stress Like Cancer

Mitochondria provide both the energy cells need to survive and the building blocks they need to grow and divide. Researchers at the Sloan Kettering Institute reveal for the first time how mitochondria choose between these opposing paths — and what implications it may have for cancer.
A hand holding a thin optical fiber giving off a red light.
In the Clinic
Light-Activated Drug Destroys Small Prostate Cancers with Fewer Side Effects

A novel treatment for prostate cancer involves a light-sensitive drug that destroys small tumors and the blood vessels that feed them.
Yonina Murciano-Goroff, Jenny Xue, Bob Li, Piro Lito, and Yulei Zhao.
Finding
MSK Researchers Are Learning Why Some Patients Develop Resistance to Targeted Lung Cancer Drug

A paper from MSK researchers reports that resistance to sotorasib, a new targeted drug for lung cancer, can be caused by many different molecular changes.
Participants in Cycle for Survival
Treating Rare Cancers

Memorial Sloan Kettering physicians have experience and specialized expertise in caring for people with uncommon cancers.
Dr. Bob Li
First Drug Targeting HER2-Mutant Non-Small Cell Lung Cancer Approved by FDA

The FDA has approved the drug trastuzumab deruxtecan for the treatment of advanced non-small cell lung cancer driven by mutant HER2. An MSK-led study published in September 2021 contributed to the drug's approval.
Through-the-microscope view of a tissue sample
MSK Research Highlights, July 17, 2023

New MSK research identified a way to reduce toxicity in CAR T cell therapy; discovered a division of labor in DNA repair that suggests a possible therapeutic strategy for certain cancers; developed a new method to enable imaging of two PET tracers simultaneously; found biomarkers that could help predict outcomes in HER2-positive metastatic esophagogastric cancer; and made progress toward improving options for patients with early-stage, potentially indolent cancers.
wedding-day photo of bride and groom embracing outside under a dramatic evening sky
A Love Story and a Legacy at MSK

Tom Scalera and Brett Ravage found a second chance at love through the MSK community after losing their spouses to cancer in 2019. Together, they have raised more than $10 million for cancer research.